Must beg to differ

Thomas Albini; Natalia F. Callaway; Glenn J. Jaffe; William Feuer; Janet Davis; Debra Goldstein; Careen Lowder; Phoebe Lin; Quan Nguyen; Sunil Srivastava; David Callanan; Anat Galor; Raquel Goldhardt; Harry Flynn

doi:10.3928/23258160-20190503-01

Must beg to differ

Thomas Albini, Natalia F. Callaway, Glenn J. Jaffe, William Feuer, Janet Davis, Debra Goldstein, Careen Lowder, Phoebe Lin, Quan Nguyen, Sunil Srivastava, David Callanan, Anat Galor, Raquel Goldhardt, Harry Flynn

Ophthalmology

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The authors provide a significant interpretation of the National Eye Institute-sponsored Multicenter Uveitis Steroid Treatment study, in which patients with severe, non-infectious intermediate, posterior, or panuveitis were randomly assigned to receive local treatment using the sutured intravitreal fluocinolone acetonide implant or systemic treatment consisting of oral steroids and conventional steroid-sparing immunosuppression, with a primary outcome of visual acuity at 2 years of follow-up. The authors also present evidence-based guidance for the treatment of noninfectious posterior segment involving uveitis.

Original language	English (US)
Pages (from-to)	266-268
Number of pages	3
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	50
Issue number	5
DOIs	https://doi.org/10.3928/23258160-20190503-01
State	Published - 2019

ASJC Scopus subject areas

Surgery
Ophthalmology

Access to Document

10.3928/23258160-20190503-01

Cite this

@article{b84fc93f00c5476389fffc31b4e73e75,

title = "Must beg to differ",

abstract = "The authors provide a significant interpretation of the National Eye Institute-sponsored Multicenter Uveitis Steroid Treatment study, in which patients with severe, non-infectious intermediate, posterior, or panuveitis were randomly assigned to receive local treatment using the sutured intravitreal fluocinolone acetonide implant or systemic treatment consisting of oral steroids and conventional steroid-sparing immunosuppression, with a primary outcome of visual acuity at 2 years of follow-up. The authors also present evidence-based guidance for the treatment of noninfectious posterior segment involving uveitis.",

author = "Thomas Albini and Callaway, {Natalia F.} and Jaffe, {Glenn J.} and William Feuer and Janet Davis and Debra Goldstein and Careen Lowder and Phoebe Lin and Quan Nguyen and Sunil Srivastava and David Callanan and Anat Galor and Raquel Goldhardt and Harry Flynn",

year = "2019",

doi = "10.3928/23258160-20190503-01",

language = "English (US)",

volume = "50",

pages = "266--268",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "5",

}

TY - JOUR

T1 - Must beg to differ

AU - Albini, Thomas

AU - Callaway, Natalia F.

AU - Jaffe, Glenn J.

AU - Feuer, William

AU - Davis, Janet

AU - Goldstein, Debra

AU - Lowder, Careen

AU - Lin, Phoebe

AU - Nguyen, Quan

AU - Srivastava, Sunil

AU - Callanan, David

AU - Galor, Anat

AU - Goldhardt, Raquel

AU - Flynn, Harry

PY - 2019

Y1 - 2019

N2 - The authors provide a significant interpretation of the National Eye Institute-sponsored Multicenter Uveitis Steroid Treatment study, in which patients with severe, non-infectious intermediate, posterior, or panuveitis were randomly assigned to receive local treatment using the sutured intravitreal fluocinolone acetonide implant or systemic treatment consisting of oral steroids and conventional steroid-sparing immunosuppression, with a primary outcome of visual acuity at 2 years of follow-up. The authors also present evidence-based guidance for the treatment of noninfectious posterior segment involving uveitis.

AB - The authors provide a significant interpretation of the National Eye Institute-sponsored Multicenter Uveitis Steroid Treatment study, in which patients with severe, non-infectious intermediate, posterior, or panuveitis were randomly assigned to receive local treatment using the sutured intravitreal fluocinolone acetonide implant or systemic treatment consisting of oral steroids and conventional steroid-sparing immunosuppression, with a primary outcome of visual acuity at 2 years of follow-up. The authors also present evidence-based guidance for the treatment of noninfectious posterior segment involving uveitis.

UR - http://www.scopus.com/inward/record.url?scp=85066271146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066271146&partnerID=8YFLogxK

U2 - 10.3928/23258160-20190503-01

DO - 10.3928/23258160-20190503-01

M3 - Review article

C2 - 31100155

AN - SCOPUS:85066271146

SN - 2325-8160

VL - 50

SP - 266

EP - 268

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

IS - 5

ER -

Must beg to differ

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this